Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paolo Malacarne is active.

Publication


Featured researches published by Paolo Malacarne.


Journal of Clinical Oncology | 1989

Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.

F. Roila; Maurizio Tonato; C Basurto; M Picciafuoco; Sergio Bracarda; D Donati; Paolo Malacarne; L Monici; F. Di Costanzo; L. Patoia

Despite treatment, emesis remains a major problem with cisplatin (CDDP) chemotherapy. Reasons for variability in antiemetic response among patients and in subsequent cycles are largely unknown and toxicity is sometimes severe. We have, therefore, carried out a multicenter, double-blind randomized trial comparing a combination of high-dose metoclopramide (MTC) (1 mg/kg x 4) and methylprednisolone (P) (treatment A) with a shorter but higher single-dose schedule of metoclopramide (3 mg/kg x 2) combined with dexamethasone (DEX) and diphenhydramine (DIP) to prevent extrapyramidal reactions (treatment B). Three hundred sixty-seven consecutive patients treated with various chemotherapy combinations containing CDDP were studied. Complete protection from vomiting/nausea was, at first cycle, 72.5%/79.5% with treatment B and 55.8%/65.1% with treatment A, a statistically significant difference (P less than .002/P less than .005). In subsequent cycles, protection from emesis significantly decreased with no difference between the two treatments. Multifactorial analysis shows that women, younger patients, outpatients, and patients who experienced emesis in previous cycles were at higher risk of suffering nausea and/or vomiting. Both regimens were well tolerated, but patients treated with treatment B had significantly less extrapyramidal reactions (1.7%/6.1%, P = .053). Treatment B is preferred due to its greater efficacy and lower incidence of extrapyramidal reactions. Trials on antiemetic therapy should take into account the important variables able to influence the efficacy of treatment. There is still a need for improving prevention of emesis in CDDP-treated patients.


Tumori | 1989

Diagnosis and first-line treatment of patients with lung cancer in Italian general hospitals

Alexan Alexanian; Giovanni Apolone; Roldano Fossati Roberto Grilli; Paola Mosconi; Antonio Nicolucci; Alessandro Liberati; G. Di Biagio; F. Testore; G. Michetti; V. Beltrami; T. Iarussi; P.L. Bonati; A. Rossetti; G.F. Buccheri; C. Manichetti; M. Indelli; Paolo Malacarne; P. Ghiringhelli; O. Olivadoti; Chiara Alessandra Cella; S. Lepore; L. Isa; R. Scapaticci; A. Sargenti; G.F. Sevieri; V. Lanzetti; O. Nascimben; E. Soresi; M. Mezzetti; C. Confalonieri

The quality of diagnostic and therapeutic care was examined in a series of 380 consecutive newly diagnosed cases of primary lung cancer seen in 20 Italian general hospitals between January and June 1987. At diagnosis most patients (78%) had one or more symptoms related to the tumor, and in an additional 9 % symptoms were related to the presence of distant metastases. The median diagnostic time lag between first symptoms and final diagnosis was 50 days with a significantly longer delay in patients first seen by their general practitioner compared with those who sought first care in hospital outpatient departments. The diagnostic process was satisfactorily carried out in fewer than two-thirds of the patients leading to complete ascertainment of disease stage and histology in 58% cases with significantly better performance in more specialized institutions. Analysis of the first-line treatment profile indicated a rather aggressive therapeutic attitude In the case of patients with non-small cell lung cancer – 28% of them had chemotherapy despite the lack of any proof of efficacy in controlled clinical trials – and a failure to identify among the patients with small cell disease those amenable to more aggressive treatment. The lack of progress in the treatment of lung cancer over the last decades seems to have resulted in widely varying practice patterns where a mixture of aggressive and laissez-faire attitudes does not take into account that in the absence of effective therapies a more conservative attitude would at least have some advantage in terms of quality of remaining life for many patients.


Research in Experimental Medicine | 1965

Die quantitative Bewertung cytologischer Veränderungen des Darmepithels im Verlaufe experimenteller Versuche mit Cytostatica

G Castoldi; Paolo Malacarne

ZusammenfassungMit Hilfe einer neuen Methode werden die Epithelzellen des Dünndarms der Maus nach Zufuhr eines Cytostaticums, Amethopterin, untersucht. Eine Verringerung der Zahl der Zellen pro Flächeneinheit sowie Chromosomenveränderungen konnten nachgewiesen werden.SummaryResults obtained by a new technic which allows the observation of great surfaces of the intestinal epithelium during different phases of experimental acute poisoning with a cytostatic drug (amethopterine) are described. A progressive decrease of the number of the epithelial cells and mitoses and an increase of the chromosomal alterations in the metaphases can be demonstrated.


Archives of Dermatological Research | 1977

Melphalan-induced melanonychia striata.

Paolo Malacarne; Giorgio Zavagli


Lung Cancer | 1991

Carboplatin (CBDOA) plus etoposide (VP16) and vicristine (VCR) in treatment of Small Cell Lung Cancer (SCLC)

Lucio Crinò; F. De Marinis; M. Clerici; M. Meacci; Giorgio Cocconi; Paolo Malacarne; F. Di Costanzo; E. Corgna; Maurizio Tonato


The Lancet | 1974

Letter: 2,4-Diaminopyrimidines and heterozygous beta-thalassaemia.

Paolo Malacarne; Giorgio Zavagli; Giuseppe Castaldi; Adriano Piffanelli


Diabetes | 1977

Tolbutamide-induced Hemolytic Anemia

Paolo Malacarne; Giuseppe Castaldi; Maurizio Bertusi; Giorgio Zavagli


The Journal of Infectious Diseases | 1971

Infectious hepatitis: a possible mitogenic factor.

Paolo Malacarne; Bruno Dallapiccola


The Lancet | 1974

2,4-DIAMINOPYRIMIDINES AND HETEROZYGOUS BETA-THALASSÆMIA

Paolo Malacarne; Giorgio Zavagli; Giuseppe Castaldi; Adriano Piffanelli


The Lancet | 1973

Au-SH ANTIGEN AND LYMPHOCYTE TRANSFORMATION

Paolo Malacarne; B Dallapiccola

Collaboration


Dive into the Paolo Malacarne's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alessandro Liberati

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chiara Alessandra Cella

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

F. De Marinis

European Institute of Oncology

View shared research outputs
Researchain Logo
Decentralizing Knowledge